Member Info for nlondon1234

Maybe Crystal have Hur as part of a risk adjusted portfolio (very small % amount of portfolio) that could admittedly outperform, like most hedgies/funds wish)).Similar to venture capital's models if you were modelling a portfolio in terms of potential returns.We all know volatility is high in hur, which could produce outperforming results.Perhaps too much pi interest is given to crystal's moves given none of us work for them and know anything about the inner workings of them imo.

I like the company and compared with others i believe it is undervalued, but not without risk obviously ( as who knows when the next molecule will be outlicenced, or how quickly already outlicenced molecules are processed through trials (as with o&g farmouts).Future potential huge and the platform clearly works!If there are future placings and you like it, just buy at the lower price too imo.This is why it isn't valued higher imo but a nasdaq listing could potentially help!

Sorry it will have some and maybe some more on indivior's trial resultss (not sure though what quantum).What i really meant was any substantial revenue yet compared to last year's placings and seemingly ongoing devolpment costs.As you most probably know the model is to eventually become self sufficient through revenue for outlicencing small molecules being developed to finance working capital and other costs.Perhaps even acquisitions and other such stuff eventually.

Trading vol has massively decreased for a company with with not insignificant market cap.I guess nobody wants to sell and nobody wants to buy!Does seem a bit weird though for the market cap.

Youch!I can't even get my tele working again.... (lost the remote)

Ddubya i heard that too at the height of the gametop saga.Unfortunately it seems 'too good to be true' as with most market stuff as institutions (ie.banks etc..) will always favour big clients as they could 'potentially' bring lots of extra 'business' with their trades.Look at Achegos.All about short term bonuses for those at the top imo.

That would be huge for Nano if it was the case and we would be way above our sp by now i reckon even if there was just speculation as somebody (in the us probably) would 'know' the ip well enough through their trading algorithms.It would have been too big to miss.Great idea though.

Yes.Watch out for China and S Korea too as government and big companies (chaebols) are intrinsically intertwined.Forget Bojo and the government's alledged few bung deals.The countries' leaderships are sneaky and play a convoluted, yet sophisticated , long game.The S Korean market has had an amazing run of late.I wonder why..........!?

I'm not a Trumpist but view his call (whether his own or of other's making and research) rather insightful.However the signs inevitably have been there for a while.Give back ARM for one (even if it wasn't bought by the Chinese and might go to the US still).

Legislation is needed.No more selling off of the family ip!We need to develop it, like with Oxford Nanopore (luckily the uni set up structures for this so it wouldn't be 'stolen' or bought cheaply a while back).

Note to Bojo, ( if he just happens to be a forum user) don't allow the sell off the country's future ip revenue, before it is fully developed and realised (if ever!)!

Oh i forgot we are main market now!

Back to business as usual in the alternative investment market then.

If sclp gets to 60p.Then i'm all in (well never 'all in' as i'm not that type).It would only start to be being valued at true value, whether through cancer or vaccine trials.It would be way more derisked and some more major funds would be able to and willing to invest imo.I reckon until a billion valuation shareholders are taking on risk.However there is always risk, just depends on your tolerance.Risk reward is pretty good here imo, if sclp get their vaccine trial going, as there is least risk in early trials failing but surely (hopefully!!) a sp appreciation if they do well as the model is further proven and derisked.

Having moved out from Richmond in London last year to the 'Surrey hills'.Sat right opposite the south downs with a view from me house and garden (can prove it with photos if necessary haha), i can confirm that they're good for walking the dogs!Let's hope the sun continues shining as it's not obviously so fab when the weather is rainy and freezing.However, surely just a little deramping might be going on here!I do agree unfortunately with aim shares sometimes soccerpunching you when least expected however.On the other hand sclp's ip is clearly in the spotlight nowadays, even if just by chance (and bad luck for the world).

Personally if you have to get some wonga out soon, i would let clear winners ride and cut back/reduce a position that historically isn't doing so great (if it is a choice between the two options only).That's a traditional approach to investing anway.However, depending on what your other investments are, we all know aim isn't always rational at times!

Are you around Luke, bones etc.. still?

I think it will be a growth thing.Once sufficient revenue starts growing, it will snowball but will take its time.Might take some time, though there is always the possibility of one or two huge orders.

Let's hope nasdaq is a better listing place and they stop shorting us!

Seems to be delayed, worked buys/sells by mms on behalf of clients for a fee.Could be funds (doubt it here as matd wouldn't qualify for most funds investing criteria).Most probably pis with larger portfolios.They tend to be favoured so as not to try spike/crash a sp if worried about that.

'no reason for the rise'

Like most of aim then.

Not revenue producing yet so not self funding.Was diluted and raised heavily again last year.Bascially the company's model isn't self funding yet and it is under the radar imo on aim and it can burn through an awful lot of cash in the meantime developing their preclinical models.So introduce unknown, potential future dilution and the value of money as a function of time into the equation as trials and milestone payments take years .The indivior trial especially long due to the litigation issues with the company imo.Quite often these type of companies are overpriced at ipo imo and take a while and more cash than expected to develop their business models.

Anyone know ,do and can us funds invest in aim (i'm not so sure?).Btw i am invested and do like the company.That's just the reason why imo.

I've been here for more than a few months and there ws heavy institutional buying pushing up the sp in the last few months.Richard Griffiths also owns circa 20%.I suspect the news was heavily sold into a while back by them.